Assembly Biosciences, Inc. (ASMB) vs Contineum Therapeutics, Inc. (CTNM)

Assembly Biosciences, Inc. and Contineum Therapeutics, Inc. are both Biotechnology companies. Assembly Biosciences, Inc. and Contineum Therapeutics, Inc. are of similar size ($481.7M and $469.9M). Contineum Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Assembly Biosciences, Inc. trades at 23.2×. Contineum Therapeutics, Inc. has the higher net margin (0.00% vs −0.06%) and the lower return on invested capital (−1,334.4% vs 0.00%). Across the 12 metrics below, Assembly Biosciences, Inc. leads on 7 and Contineum Therapeutics, Inc. on 5.

Valuation

Metric ASMB CTNM Biotechnology median
P/E 23.21 n/m 7.88
P/S 5.96 n/m 11.47
P/B 1.46 1.96 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.68 n/m 10.73
Earnings yield 4.31% (13.77%) (28.84%)
Free cash flow yield (8.64%) (11.36%) (23.03%)

Profitability

Metric ASMB CTNM Biotechnology median
Gross margin 100.00% — 65.16%
Operating margin (11.75%) 0.00% 0.00%
Net margin (0.06%) 0.00% 0.00%
Free cash flow margin (51.53%) 0.00% 0.00%
Return on equity (0.03%) (28.01%) (57.72%)
Return on assets (0.02%) (26.57%) (49.22%)
Return on invested capital 0.00% (1,334.41%) 0.00%

Growth

Metric ASMB CTNM Biotechnology median
Revenue growth (TTM) 125.12% — 5.64%
EPS growth (last fiscal year) 91.78% 0.46% —
Revenue growth, 5-year CAGR 35.27% — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric ASMB CTNM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 13.99 37.17 4.73
Net debt to EBITDA 17.31 3.88 0.96

Dividend

Metric ASMB CTNM Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric ASMB CTNM Biotechnology median
Market cap 481.73m 469.89m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack